Abstract
Therapeutic management of cancer has undergone tremendous conceptual advance over the last couple of decades. Not only are we better acquainted with the intricate mechanisms leading to oncogenic transformation, but also the strategies to intercept and disturb these command and control pathways are becoming more specific and target-selective. One critical change is the realization that despite the existence of diverse mechanisms for the development of different sub-sets of cancers, there may indeed be central regulatory networks that serve as a common denominator in all forms of neoplasia. These critical events could endow cells with the potential for unabated proliferation, insensitivity to death inducing signals, and enhanced metastatic potential. Thus, developing strategies to target these critical events or pathways should significantly improve the outcome of cancer chemotherapy. The purpose of this review is to briefly discuss the complexities of the disease, highlight the current therapeutic strategies, and more importantly provide a mechanistic approach for future drug design aimed at targeting the traits of the disease and for favorably tailoring the response of cancer cells to drug therapy.
Keywords: anti-cancer drugs, curing cancer, therapeutic management, neoplasia, drug therapy, mechanistic approach to the design, antibiotics, novel strategies, fptase activity, remortalize the immortal
Current Pharmaceutical Design
Title: Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Volume: 8 Issue: 19
Author(s): Shazib Pervaiz
Affiliation:
Keywords: anti-cancer drugs, curing cancer, therapeutic management, neoplasia, drug therapy, mechanistic approach to the design, antibiotics, novel strategies, fptase activity, remortalize the immortal
Abstract: Therapeutic management of cancer has undergone tremendous conceptual advance over the last couple of decades. Not only are we better acquainted with the intricate mechanisms leading to oncogenic transformation, but also the strategies to intercept and disturb these command and control pathways are becoming more specific and target-selective. One critical change is the realization that despite the existence of diverse mechanisms for the development of different sub-sets of cancers, there may indeed be central regulatory networks that serve as a common denominator in all forms of neoplasia. These critical events could endow cells with the potential for unabated proliferation, insensitivity to death inducing signals, and enhanced metastatic potential. Thus, developing strategies to target these critical events or pathways should significantly improve the outcome of cancer chemotherapy. The purpose of this review is to briefly discuss the complexities of the disease, highlight the current therapeutic strategies, and more importantly provide a mechanistic approach for future drug design aimed at targeting the traits of the disease and for favorably tailoring the response of cancer cells to drug therapy.
Export Options
About this article
Cite this article as:
Pervaiz Shazib, Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?, Current Pharmaceutical Design 2002; 8 (19) . https://dx.doi.org/10.2174/1381612023394025
DOI https://dx.doi.org/10.2174/1381612023394025 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology The Association Between HIV/AIDS During Pregnancy and Fetal Growth Parameters in Florida: A Population Based Study
Current HIV Research Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain
Current Pharmaceutical Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Involvement of Metallothioneins in Mitochondrial Function and Disease
Current Protein & Peptide Science Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Wogonin Alleviates Hyperglycemia Through Increased Glucose Entry into Cells Via AKT/GLUT4 Pathway
Current Pharmaceutical Design Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent
Current Topics in Medicinal Chemistry Cardiospecific Troponins as Laboratory Biomarkers of Myocardial Cell Injury in Hypertension: A Mini-Review
Current Medicinal Chemistry Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews Molecule of the Month
Current Topics in Medicinal Chemistry Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Human Myoblast Genome Therapies and Devices in Regenerative Medicine
Recent Patents on Regenerative Medicine Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews Clinical Application of Ghrelin
Current Pharmaceutical Design